A Proposed, Evidence-based Approach to the Treatment of Chronic Hepatitis B

[Guest guest]

http://journals.lww.com/jcge/Abstract/2011/03000/A_Proposed,_Evidence_based_Appr\

oach_to_the.12.aspx

Journal of Clinical Gastroenterology:

March 2011 - Volume 45 - Issue 3 - p 259–266

doi: 10.1097/MCG.0b013e3181f312f5

LIVER, PANCREAS AND BILIARY TRACT: Clinical Review

A Proposed, Evidence-based Approach to the Treatment of Chronic Hepatitis B

Han, -Huy B. MD; Durazo, Francisco A. MD; Saab, Sammy MD, MPH; Tong, Myron

J. MD, PhD

Abstract

Patients with chronic hepatitis B virus infection are at increased risk for the

development of cirrhosis and hepatocellular carcinoma. Viral suppression with

antiviral therapy has been shown to decrease the risk of these complications.

Criteria for initiation of antiviral therapy have evolved over time to include

serum alanine aminotransferase elevation, serum hepatitis B virus DNA

elevations, and histologic assessment. Current societal guidelines and a

treatment algorithm have been developed to guide decision-making as regards to

antiviral therapy. More recent data has shown the importance of basal core/core

promoter mutations, serum albumin, and platelet count in predicting

complications of chronic hepatitis B. We present a new treatment strategy for

determining the need for antiviral therapy in patients with chronic hepatitis B.

© 2011 Lippincott & Wilkins, Inc.

[Guest guest]

http://journals.lww.com/jcge/Abstract/2011/03000/A_Proposed,_Evidence_based_Appr\

oach_to_the.12.aspx

Journal of Clinical Gastroenterology:

March 2011 - Volume 45 - Issue 3 - p 259–266

doi: 10.1097/MCG.0b013e3181f312f5

LIVER, PANCREAS AND BILIARY TRACT: Clinical Review

A Proposed, Evidence-based Approach to the Treatment of Chronic Hepatitis B

Han, -Huy B. MD; Durazo, Francisco A. MD; Saab, Sammy MD, MPH; Tong, Myron

J. MD, PhD

Abstract

Patients with chronic hepatitis B virus infection are at increased risk for the

development of cirrhosis and hepatocellular carcinoma. Viral suppression with

antiviral therapy has been shown to decrease the risk of these complications.

Criteria for initiation of antiviral therapy have evolved over time to include

serum alanine aminotransferase elevation, serum hepatitis B virus DNA

elevations, and histologic assessment. Current societal guidelines and a

treatment algorithm have been developed to guide decision-making as regards to

antiviral therapy. More recent data has shown the importance of basal core/core

promoter mutations, serum albumin, and platelet count in predicting

complications of chronic hepatitis B. We present a new treatment strategy for

determining the need for antiviral therapy in patients with chronic hepatitis B.

© 2011 Lippincott & Wilkins, Inc.